Souza MM, Díaz BSL, Guisa CVM

Language: Spanish
References: 203
Page: 386-405
PDF size: 126.61 Kb.

ABSTRACT

This paper presents a thematic revision of the substitution treatment with buprenorphine, BPNA, for opiate abusers/addicts, which shows the current clinical situation of abuse and addiction to opiates (natural and synthetic), their main effects and other pharmacologic antecedents. The succinct description of the urgent wish-necessity of consumption, D-NIC (craving) and its searching conduct for the substance, bases the clinical context and the necessary professional management for this issue. BPNA is described as the substance of first election in substitute management of certain patients, its pertinent characteristics and recommendations for ambulatory administrationism pharmacology and pharmacokinetic, clinical use, opiate gradual reduction as goal for management of chosen users, the use of opiate antagonists and medical management of abstinence; psychotherapeutic modalities available around the Relapse Prevention Program, and if it is the case, the confined management of patients through a special treatment (Therapeutic Community). The documented convenience of its use is discussed, comparing it with methadone hydrochloride, MH, used at the moment in many programs for the treatment of opiates abusers/addicts around the world; the paper concludes with the revision of advantages/disadvantages of the use of BPNA.

REFERENCES

1. Centros de Integración Juvenil, AC. Programa de Deshabituación y Mantenimiento con Buprenorfina. Subdirección de Hospitalización y Proyectos Clínicos. México, 2005.

2. SAMHSA. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Summary of findings from 1998 National Household Survey on Drug Abuse; 1998.

3. Sloboda Z. Drug abuse patterns in the US National Institute on Drug Abuse. Community Epidemiology Work Group. Epidemiologic trends in drug abuse. Volume II. Proceeding of the International Epidemiology Work Group on Drug Abuse. Rockville (MD): National Institute on Drug Abuse; 1999, p. 135-8.

4. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: A current perspective. West J Med 1990; 152: 588-99.

5. Ellenhorn M. Medical toxicology. Diagnosis and treatment of human poisoning. William and Wilkins; 1997.

6. Jasinski DR, Martin WR. Assessment of the dependenceproducing properties of dihydrocodeinone and codoxime. Clin Pharmacol Ther 1967; 8: 266-70.

7. Martin WR, Jasinski D. Psychological parameters of morphine in man: tolerance, early abstinence, prottracted abstinence. J Psychiatry Res 1969; 7: 9-17.

8. Shippenberg TS, Elmer GI. The neurobiology of opiate reinforcement. Crit Rev Neurobiol 1998; 12: 267-303.

9. Mello NK, Mendelson JH, Lukas SE, Gastfriend DR, Teoh SK, Holman BL. Buprenorphine treatment of opiate and cocaine abuse: Clinical and preclinical studies. Harv Rev Psychiatry 1993; 1(3): 168-83.

10. Souza y MM, Díaz Barriga SL, Guisa CVM. Adicciones: neuroquímica y terapéutica. Rev Mex Neuroci 2004; 5(6): 619-34.

11. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715-23.

12. National Consensus Development Panel on Effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-43.

13. Gold MS, Redmond DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2: 599-602.

14. Washton AM, Resnick RB. Clonidine for opiate detoxification: outpatient clinical trials. Am J Psychiatry 1980; 137: 1121-2.

15. Charney DS, Sternberg DE, Kleber HD. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 1981; 38: 1273-7.

16. Kleber HD, Riordan CE, Rounsaville B. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 1985; 42: 391-4.

17. Asin KE, Wirtshafter D. Clonidine produces a conditioned place preference in rats. Psychopharmacology 1985; 85: 383-5.

18. Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995; 12: 35-41.

19. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch Gen Psychiatry 1978; 35: 335-40.

20. Volpicelli JR, O’Brien CP, Alterman AI, Hayashida M. Naltrexone and the treatment of alcohol dependence: initial observations. In: REID LD, editor. Opioids, bulimia and alcohol abuse and alcoholism. New York: Springer Verlag; 1990, p. 195-214.

21. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M. Predicting treatment response in naltrexone: the influence of craving and family history. Am J Addict 2001; 10: 258-68.

22. Preuss UW, Koller G, Soyka M, Bondy B. Association between suicide attempts and 5-HTTLPR-S-allele in alcohol- dependent and control subjects: further evidence from a German alcohol-dependent in patient sample. Biol Psychiatry 2001; 50: 636-9.

23. Guisa CVM, Díaz Barriga SL, Souza y MM. Terapéutica antiadictiva, utilidad de sus factores de predicción. Rev Mex Neuroci 2004; 5(6): 581-98.

24. Kranzler H, Lappalainen J, Nellissery M, Gelernter J. Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. Alcohol Clin Exp Res 2002; 26: 1330-5.

25. Veenstra-Vanderweele J, Anderson GM, Cook EH. Pharmacogenetics and serotonin system: initial studies and future directions. Eur J Pharmacol 2000; 410: 165-81.

26. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 1997; 129: 99-111.

27. Kosten TR. The pharmacotherapy of relapse prevention using anticonvulsants. Am J Addict (Summer) 1998; 7(3): 205-9.

28. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53: 250-7.

29. Curren S, Savage C. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration. NIDA Res Monogr 1976; 9: 67-9.

30. Hollister LE. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the national research council committee on clinical evaluation of narcotic antagonists. Arch Gen Psychiatry 1978; 35(3): 335-40.

31. San L, Pomarol G, Peri JM. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991; 86: 983-90.

32. Lerner A, Sigal M, Bacalu A. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci 1992; 29: 36-43.

33. Shufman EN, Porat S, Witztum E. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994; 35: 935-45.

34. Rabinowitz J, Cohen H, Tarrasch R. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend 1997; 47: 77-86.

35. Gerra G, Zaimovic A, Rustichelli P. Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance. J Subst Abuse Treat 2000; 18: 185-91.

36. Marrazzi MA, Wroblewski JM, Kinzie J. High-dose naltrexone and liver function safety. Am J Addict 1997; 6: 21-9.

37. Hulse GK, Basso MR. Reassessing naltrexone maintenance as a treatment for illicit heroin users. Drug Alcohol Rev 1999; 18(3): 263-9.

38. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2 (CD001333), 2001.

39. Oficina de las Naciones Unidas Contra la Droga y el Delito, PNUFID. Tratamiento contemporáneo del abuso de drogas: análisis de las pruebas científicas. N.Y.: ONU; 2003.

40. Hales RE, Yudofsky SC, Talbott JA. Tratado de Psiquiatría. 3th. Ed. American Psychiatric Press-Masson, Multimedia 2000.

41. Eddy NB, Halbach H, Braenden OJ. Synthetic substances with morphine-like effect - clinical experience: potency, side-effects, addiction liability. 5. Hydrocodone (dihydrocodeinone). Bull WHO 1957; 17: 595-600.

42. Goodman and Gillman. Las Bases Farmacológicas de la Terapéutica. 9a. Ed. McGraw-Hill & Interamericana; 1996.

43. Ling W, Wesson DR. Drugs of abuse: opiates. In: Addiction Medicine (Special Issue). West J Med 1990; 152: 565-72.

44. National Institute on Drug Abuse, NIDA. Methadone in maintenance and detoxification: Joint revision of conditions for use, 1989; 54: 8954.

45. Souza y MM. Filosofía y políticas de los programas terapéuticos contra las adicciones. Subdirección de Hospitalización y Proyectos Clínicos. Centros de Integración Juvenil, A.C. México, 2004.

46. Sánchez-Hervás E, Molina N, Del Olmo R, Tomás V, Morales E. Craving y adicción a drogas. Trastornos Adictivos 2001; 3: 237-43.

47. Souza y MM. Diagnóstico y Tratamiento de los Síndromes Adictivos. México: Editorial Ciencia y Cultura Latinoamérica; 2000.

48. Souza y MM, Martínez AJ, Mercado CG. Consideraciones sobre la Farmacoterapia del Alcoholismo. Psiquiatría 1999; 2; 5(1): 12-19.

49. Chiang SSW, Schuetz CG, Soyka M. Role of aggressivity on reactivity and craving before and after cue exposure in recently detoxified alcoholics: results from an experimental study. Eur Addict Res 2001; 7: 184-92.

50. NIH Consensus Panel. Effective medical treatment of opiate addiction, EMTOA. National consensus development panel EMTOA. JAMA 1999; 280(22): 1936-43.

51. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA 1995; 273: 1619-20.

52. Van Der Burgh C. A review of the drug abuse situation in the world. National Institute on Drug Abuse. Community Epidemiology Work Group. In: Epidemiologic trends in drug abuse. Volume II: Proceeding of the International Epidemiology Work Group on Drug Abuse. Rockville (MD): National Institute on Drug Abuse 1999; 135-8.

53. Novick DM, Pascarelli EF, Joseph H. Methadone maintenance patients in general medical practice. A preliminary report. JAMA 1998; 259: 3299-302.

54. Rommelspacher H, Smolka M, Schmidt LG. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 2001; 24: 129-35.

55. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21: 46776.

56. Marlatt GA. Craving for alcohol, loss of control, and relapse: a cognitive behavioral analysis. In: Marlowe K. Opiate withdrawal and botulism: stigma delayed treatment. BMJ 2003; 12; 326(7393): 822.

57. Souza y MM, Martínez AJ, Martínez MJ, Mercado CG, Tagle OI. Craving, adicción etílica y terapéutica. Arch Neurociencias México 2000; 5(4): 201-4.

58. Souza y MM. Programa profesional terapéutico contra las adicciones. Una propuesta integrativa. Psiquiatría 2005: 21(1): 25-37.

59. Olivares HM, Tagle OI, Mercado CG, Souza y MM. Psicodinamia y psicoterapia del paciente adicto. Psiquiatría 2003; 19(1): 28-38.

60. Souza y MM. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004; 5(1): 57-69.

61. Prochaska JO, Diclemente CC, Norcross JC. In search of how people change. Applications to addictive behaviour. Am Psychol 1992; 47: 1102-14.

62. Prochaska JO, Prochaska JM. Modelo transteorético de cambio para conductas adictivas. En: CASA M, GOSSOP M. (Eds). Recaída y prevención de recaídas. Barcelona: Neurociencias; 1993, p. 85-136.

63. Guisa CVM, Díaz Barriga SL, Souza y MM. Terapéutica antiadictiva: utilidad de sus factores de predicción. Rev Mex Neuroci 2004.

64. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA 2000; 283(10): 1337-9.

65. McNicholas L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. A Treatment Improvement Protocol. TIP 40 U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. DHHS Publication No. (SMA) 04-3939. 2004.

66. Diario Oficial. Norma Oficial Mexicana NOM 028-SSA2- 1999 para la Prevención, Tratamiento y Control de las Adicciones. Viernes 18 de Agosto de 2000.

67. Diario Oficial. Proyecto de Norma Oficial Mexicana NOM- 168-SSA1-1998, del Expediente Clínico. Lunes 7 de Diciembre de 1998.

68. Norma Oficial Mexicana NOM-025-SSA2-1994 para la prestación de servicios de salud en unidades de atención integral hospitalaria médico-psiquiátrica. Diario Oficial. Ciudad de México, miércoles 15 de noviembre de 1995.

69. Caplehorn Jr, Dalton MS, Cluff MC. Retention in methadone maintenance and heroin addicts’ risk of death. Addiction 1994; 89: 203-9.

70. Ward J, Bell J, Mattick RP. Methadone maintenance therapy for opioid dependence: A guide to appropriate use. CNS Drugs 1996; 6(6): 440-9.

71. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991, p. 212-32.

72. Lowinson JH, Payte JT, Salsitz E. Methadone Maintenance. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG. Substance Abuse. 3a. Ed. USA: William & Wilkins; 1997, 41: 405-15.

73. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2: 485.

74. Reilly PM, Bayns P, Tusel DJ. Methadone transition treatment: a treatment model for 180 day methadone detoxification. Int J Addictions 1995; 30: 387-402.

75. Novick DM, Joseph H, Salsitz EA. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians’ offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med 1994; 9: 127-30.

76. Barrau K, Thirion X, Micallef J. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96(10): 1433-41.

77. Kosten TR, Schottenfeld R, Ziedonis D. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181: 358-64.

78. Resnick RB, Galanter M, Pycha C. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 1992; 28: 109-13.

79. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991; 17: 119-28.

80. Johnson RE, Chutuape MA, Strain EC. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-7.

81. Melvin Pohl. Guidelines for HIV infection and aids in addiction treatment. American Society of Addiction Treatment; 1998.

82. Martínez AJ, Martínez MJ, Mercado CG, Souza y MM, Prado GA. Binomio sida-adicciones: un reto para la psiquiatría en los umbrales del nuevo milenio. Psiquiatría 1999; 15(3): 61-7.

83. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate-withdrawal among injection drug users with HIVinfection receiving methadone. AIDS 1999; 13: 957-62.

84. AMA. AMA Drug Evaluations, 6th ed. American Medical Association, Chicago, IL, 1986.

85. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995; 15(1): 49-57.

86. Fishbain DA, Rosomoff HL, Cutler R. Opiate detoxification protocols, a clinical manual. Ann Clin Psychiatry 1993; 5: 53-65.

87. Wesson DR. Detoxification From Alcohol and Other Drugs. Treatment Improvement Protocol (TIP) Series 19, Consensus Panel Chair, U.S. Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Services Administration, Printed 1995.

88. NIDA. Principios de Tratamientos para la Drogadicción, Una Guía Basada en Investigaciones, NIDA, Julio 2001.

89. Graham K. The cell biology of neurons. Department of Biochemistry. The University of Queensland, Australia; 1999.

90. Dipaula BA, Schwartz R, Montoya ID, Barrett D, Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. J Subst Abuse Treat 2002; 23(3): 163.

91. Blaine JD (ed). Buprenorphine: An alternative Treatment for opioid dependence. NIDA Research Monograph 121. Washington DC; NIDA; 1992.

92. Gowing L, Alí R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews. 2000, CD002025.

93. Senay EC, Dorus W, Goldberg F. Withdrawal from methadone maintenance. Arch Gen Psychiatry 1977; 34: 361-7.

94. Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 531-8.

95. Petry NM, Bickel WK, Badger GJ. Examining the limits of the buprenorphine interdosing interval: daily, everythird- day and every-fifth-day dosing regimens. Addiction 2001; 96: 823-34.

96. Walsh SL, Preston KL, Bigelow GE. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361-72.

97. Joint Formulary Committee 2004. British National Formulary (47th ed.). London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004.

98. Umbricht A, Montoya ID, Hoover DR. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend 1999; 56: 181-90.

99. Nigam A, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 1993; 10: 391-4.

100. Iribarne C, Berthou F, Carlhant D. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26: 257-60.

101. Food and Drug Administration, FDA. MedWatch. Orlaam. In: Index of Safety-Related Drug Labeling Change Summaries. Approved by FDA center for drug evaluation and research (CDER), 2005.

102. Kuhlman JJ, Levine B, Johnson RE. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549-59.

103. Judson BA, Goldstein A. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts. I. Dosage schedule for induction and stabilization. Drug Alcohol Depend 1979; 4: 461-6.

104. Tennant FS, Rawson RA, Pumphrey E. Clinical experiences with 959 opioid-dependent patients treated with levoalphaacetylmethadol (LAAM). J Subst Abuse Treat 1986; 3: 195-202.

105. Huestis MA, Umbricht A, Preston KL. Safety of buprenorphine: no clinically relevant cardio-respiratory depression at high IV doses. In: Harris LS, Ed. Problems of Drug Dependence. NIDA Res Monogr. Washington (DC): U.S. Government Printing Office 1999; 179: 62.

106. Rance MJ, Dickens JN. The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine. In: Van Ree JM, Pereniums L, Eds. Characteristics and function of opioids. Amsterdam: Elsevier/North-Holland Biomedical Press; 1978, p. 65-6.

107. Amass L, Bickel WK, Higgins ST. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994; 13: 33-45.

108. Lange WR, Fudala PJ, Dax EM. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1990; 26: 19-28.

109. Kleber HD, Topazan M, Gaspari J. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13: 1-17.

110. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002; 303(2): 695-703.

111. Kosten TR. Farmacoterapia para el abuso de opioides y cocaína. Clínicas Médicas de Norteamérica 1997; 4: 893-910.

112. Mattick RP, Kimber J, Breen C, Davoli M. Mantenimiento con buprenorfina versus placebo o mantenimiento con metadona para la dependencia de opiáceos. Biblioteca Cochrane Plus, Oxford 2005; 4: 18-27.

113. Hovell BC, Ward AE. Pain relief in the post-operative period: A comparative trial of morphine and a new analgesic buprenorphine. J Int Med Res 1977; 5: 417.

114. Chang G, Kosten TR. Detoxification. In: Substance Abuse. A comprehensive Textbook. 3rd ed. Williams & Wilkins; 1997.

115. Jaffe JH, Knapp CM, Ciraulo DA. Opiates: Clinical Aspects. Lowinson JH, Ruiz P, Millman RB, Langrod JG. Substance Abuse. 3a. Edition. Williams & Wilkins 1997; 14: 158-16.

116. Commitee to Study Medication Development and Research at National Institute on Drug Abuse. In: Fulco CE, Liverment CT, Earley LE (Eds). The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Goverment and Private Sector. Washington DC: National Academy Press; 1995.

117. Heel RC, Brogden RN, Speight TM. Buprenorphine: A review. Drugs 1979; 17: 82-110.

118. Jasinski DR, Fudala PJ, Johnson RE. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 1989; 45: 513-19.

119. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750-5.

120. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002; 97(11): 1395-404.

121. Kutz I, Reznik V. Heroin detoxification with a single high dose of buprenorphine. Isr J Psychiatry Relat Sci 2002; 39(2): 113-9.

122. Piola JC, Prada DB. Aspectos médicos toxicológicos en pacientes con adicción a drogas atendidos en Rosario. En “Adicciones. Desafíos y abordajes”. Salud en el Municipio de Rosario. El Rosario, Argentina: Ed. Secretaría de Salud Pública; 1998, p. 105-10.

123. Seifert J, Metzner C, Paetzold W, Borsutzky M, Passie T, Rollnik J. Detoxification of opiate addicts with multiple drug abuse: A comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002; 35(5): 159- 64.

124. White JM. Mechanisms of fatal opiod overdose. Addiction 1999; 94(7): 961-72.

125. Lavignasse P, Lowenstein W, Batel P, Constant MV, Jourdain JJ. Economic and social effects of high-dose buprenorphine substitution therapy. Six-month results. Ann Med Interne (Paris) 2002; 153(3 Suppl.): 1S20-6.

126. Jasinski DR, Martin WR, Griffith JD. Human pharmacology and abuse potential of analgesic buprenorphine. Arch Gen Psychiatry. 1978; 35: 601 (Joint Formulary Committee, 2004).

127. Canadell-Carafi J, Moreno-Londono A, Gonzalez- Caudevilla B. Ketorolac, a new non-opioid analgesic: a single-blind trial versus buprenorphine in pain after orthopaedic surgery. Curr Med Res Opin 1991; 12(6): 343-9.

128. Telias D, Nir-Hod J. Buprenorphine-ketorolac vs. clonidine-naproxen in the withdrawal from opioids. Int J Psychosocial Rehabilitation 2000; 5: 29-33.

129. Bakris GL, Cross PD, Hammarsten JE. The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc 1982; 57: 657-60.

130. Ghodse H, Myles J, Smith SE. Clonidine is not a useful adjunt to methadone gradual detoxification in opioid addiction. Br J Psychiatry 1994; 165: 370-4.

131. Janiri L, Mannelli P, Persico AM. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994; 36: 139-45.

132. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine/clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36: 115-21.

133. Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: A review. Exp Clin Psychopharmacol 1995; (3): 477-89.

134. Bickel WK, Amass L, Higgins ST. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol 1997; 65: 803-10.

135. Souza y MM. Nosología y propedéutica de los programas antiadictivos. Rev Mex Neuroci 2005; 6(2): 166-79.

136. Oficina de las Naciones Unidas Contra la Droga y el Delito (ONUDD). Abuso de drogas: tratamiento y rehabilitación. Guía de planificación y aplicación. Capítulo VI. Integración efectiva de los servicios de tratamiento. Naciones Unidas. Viena, 2003.

137. O’Connor PG, Waugh ME, Carroll KM. Primary carebased ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med 1995; 10: 255-60.

138. Scherbaum N, Klein S, Kaube H. Alternative strategies of opiate detoxification: evaluation of the so-called ultrarapid detoxification. Pharmacopsychiatry 1998; 31: 205-9.

139. O’Connor PG, Fiellin DA. Pharmacologic treatment of heroindependent patients. Ann Intern Med 2000; 133: 40-54.

140. Albanese AP, Gevirtz C, Oppenheim B. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). J Addict Dis 2000; 19: 11-28.

141. Lawental E. Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program, a retrospective follow-up study. J Subst Abuse 2000; 11: 173-81.

142. Loimer N, Schmid R, Presslich O. Naloxone treatment for opiate withdrawal syndrome. Br J Psychiatry 1988; 153: 851-2.

143. Stoller KB, Bigelow GE, Walsh SL. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacologia 2001; 154: 230-42.

144. Charney DS, Riordan CE, Kleber HD, Murburg M, Braverman P, Sternberg DE. Clonidine and naltrexone. Arch Gen Psychiatry 1982; 39: 1327-32.

145. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addiction 1988; 83: 567-75.

146. Traub SL. Clonidine for opiate withdrawal. Hosp Formul 1985; 20: 77-80.

147. Washton AM, Resnick RB. Outpatient opiate detoxification with clonidine. J Clin Psychiatry 1982; 43: 39-41.

148. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002; 13(5-6): 355-66.

149. Lintzeris N. Buprenorphine dosing regime in the management of out-patient heroin withdrawal. Drug Alcohol Rev 2002; 21(1): 39-45 37.

150. Galanter M. Textbook of Substance Abuse Treatment Second Edition; 1999.

151. Fudala PJ, Bridge TP, Herbert S. A multisite efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment. Rockville (MD): DHHS/ NIH/NIDA. NIDA Res Monogr 1998; 179: 105.

152. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58: 143-52.

153. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphinenaloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001; 61: 173-81.

154. Vignau J, Brunelle E. Differences between general practitionerand addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res 1998; 4(Suppl. 1): 24-8.

155. Tracqui A, Kintz P, Ludes B. Buprenorphine-Related deaths among drug addicts in France: Areport on 20 fatalities. J Anal Toxicol 1998; 22: 430-3.

156. Thirion X, Micallef J, Barrau K. Recent evolution in opiate dependence in France during generalization of maintenance treatments. Drug Alcohol Depend 2001; 61: 281-5.

157. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65-9.

158. Obadia Y, Perrin V, Feroni I. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267-72.

159. Adinoff B. Neurobiologic Processes in Drug Reward and Addiction. Harv Rev Psychiatry 2004; 12: 305-20.

160. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of psychiatry. 7a. Ed. Washington: William and Wilkins; l994.

161. Ling W, Smith D. Buprenorphine: blending practice and research. J Subst Abuse Treat 2002; 23(2): 8738.

162. O’Brien CP. Adicción y abuso de sustancias tóxicas. In: Goodman & Gillman. Las Bases Farmacológicas de la Terapéutica. 9a. Ed. McGraw-Hill Interamericana; 1996, p. 605-8.

163. Souza y MM, Quijano Bem, Díaz Barriga SL, Guisa CVM, Lorenzo AS, Gaucín RR. Historia Clínica Psiquiátrica Codificada para Adicciones, HCCPA. Psiquiatría 1998; 14(1): 13-25.

164. Wilkerson D, Migas N, Slaven T. Outcome-oriented standards and performance indicators for substance dependency rehabilitation programs. Subst Use Misuse 2000; 35(12-14): 1679-703.

165. Judson BA, Goldstein A, Inturrisi CE. Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Doubleblind comparison of gradual and abrupt detoxification. Arch Gen Psychiatry 1983; 40: 834-40.

166. Margolin A, Kosten TR. Opioid detoxification and maintenance with blocking agents. In: Miller NS, editor. Comprehensive handbook of drug and alcohol addiction. New York: Arcel Dekker; 1991, p. 1127-47.

167. O’Connor PG, Carroll KM, Shi JM. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 1997; 127: 526-30.

168. Substance Abuse and Mental Health Services Administration, SHAMSA. Opioid drugs in Maintenance and Detoxification Treatment of Opiate Addiction 2001; 66(11): 4076-102.

169. Walsh SL, Preston KL, Stitzer ML. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-80.

170. Ellenhorn MJ, Barceloux DG. Medical toxicology. Diagnosis and treatment of human poisoning. New York: Elsevier; 1988, p. 67.

171. Meredith TJ, Jacobsen D, Haines JA, Berger JC, Eds. Naloxone, flumazenil and dantrolene as antidotes. Cambridge: University Press; 1993.

172. Martínez CJ, Acosta ME, Pomier SO. Errores más frecuentes en la atención al paciente intoxicado. Rev Cubana Med Gen Integr 1998; 14(1): 7-14.

173. Souza y MM. Personalidad y adicciones. Rev Mex Neuroci 2005; 6(4): 336-45.

174. Bellack L, Smmall L. Emergency Psychotherapy and Brief Psychotherapy. Second edition. Grune and Stratton. New York, 1978.

175. Sánchez-Hervás E, Gradolí VT, Morales GE. Un modelo de tratamiento psicoterapéutico en adicciones. Trastornos Adictivos 2004; 6(3): 159-66.

176. Strupp HH. On the basic ingredients of psychotherapy. J Consul Clin Psychol 1973; (41): 1.

177. Wolberg L. Short term psychotherapy. New York: Grune and Stratton; 1965.

178. Karasu T, Steinmuller RI. Psychotherapeutics in medicine. New York: Ed. Grune and Stratton; 1978.

179. Miller NS, Gold MS. Dissociation of conscious desire: craving from and relapse in alcohol and cocaine dependence. Ann Clin Psychiatry 1994; 6: 99-106.

180. Souza y MM. Consideraciones y fundamentos para una terapéutica profesional de las adicciones. Rev Mex Neuroci 2003; 4(5): 326-30.

181. Naciones Unidas. Oficina contra la Droga y el Crimen, UNODC. Reporte Mundial Sobre Drogas 2004. ONU. Ginebra, 2004.

182. SSA, CONADIC, INPRFM, DGE, INEGI. Encuesta Nacional de Adicciones 2002. México 2003.

183. Ling W, Wesson DR. Drugs of abuse: opiates. In: Addiction Medicine. West J Med 1990; 152: 565-72.

184. American Psychiatric Association, APA. Diagnostical and Statistical Manual of Mental Disorders, DSM-IV-TR. Washington; 2000.

185. Johnson RE, JAFFE JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750-5.

186. Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001; 63: 253-62.

187. Loimer N, Schmid R, Lenz K. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990; 157: 748-52.

188. Díaz Barriga SL, Souza y MM, Romero RR, Quijano BEM, Guisa CVM. Marco conceptual y consideraciones para la evaluación de programas antiadictivos. Dirección General Adjunta Normativa. México: Centros de Integración Juvenil, A.C.; 2005.

189. Servicio Central de Publicaciones del Gobierno Vasco. Drogodependencias: reducción de daños y riesgos. Departamento de Justicia, Trabajo y Seguridad Social. Vitoria-Gasteiz; 2000.

190. Simpson DD. National Treatment System Evaluation based on the Drug Abuse Reporting Program (DARP) follow-up research. In: TIMS FM; LUDFORD JP: (Eds.). Drug abuse treatment evaluation: Strategies, Progress and Prospects. National Institute of Drug Abuse (NIDA). Research Monography 51. Washington: DHHS Pub. (ADM); 1984, 84; 1329: 29-41.

191. Colom J. Los programas de reducción de riesgos. Adicciones 1997; 2, p. 163-70.

192. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990; 82: 223-7.

193. Souza y MM. El papel de la mitología popular, la semántica y la iatrogenia en las adicciones. Rev Mex Neuroci 2001; 2(1): 25-7.

194. Caplehorn JR, Irwig L, Saunders JB. Physicians attitudes and retention of patients in their methadone maintenance programs. Substance Use and Misuse 1996; 31(6): 663-77.

195. Oficina de las Naciones Unidas Contra la Droga y el Delito, PNUFID. Tratamiento contemporáneo del abuso de drogas: análisis de las pruebas científicas. New York: ONU; 2003.

196. American Society of Addiction Medicine, ASAM. Public policy statement on screening for addiction in primary care settings. ASAM News 1997; 17: 17-18.

197. Des Jarlais DC, Paone D, Fridman SR. Regulating controversial programs for unpopular people: Methadone Maintenance and syringe exchange programs. Am J Public Health 1995; 85(11): 1577-84.

198. Ling W, Charuvastra C, Collins JF. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93: 475-86.

199. Souza y MM. Por una psiquiatría de las adicciones. Rev Mex Neuroci 2003; Editorial 4(4): 206-8.

200. Tagle OI, Mercado CG, Martínez AJ, Martínez MJ, Souza y MM. Por qué profesionalizar la terapéutica de las adicciones. Psiquiatría 2000; 16(3): 110-16.

201. Souza y MM, Guisa CVM, Díaz Barriga SL. Hacia una integración nacional de la terapéutica antiadictiva. Rev Mex Neuroci 2005; 6(5): 411-25. 202. Dole VP, Joseph H. Long-term outcome of patients treated with methadone maintenance. Ann NY Acad Sci 1978; 311: 181.

202. Souza y MM. Enseñanza e Investigación en Adicciones en la Ciudad de México. Psiquiatría. 1998; 14(3): 100-6.

203. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94: 479-88.